Levosimendan: Dual mechanisms for acute heart failure... and beyond?

Minerva Cardioangiologica

Volumn 53, Issue 6, 2005, Pages 565-584

  Ng, T M H ^a   Akhter, M W ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Calcium sensitizer; Heart failure, congestive; Levosimendan; Vasodilators

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADRENALIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOBUTAMINE; GLYCERYL TRINITRATE; LEVOSIMENDAN; MILRINONE; NESIRITIDE; NITROPRUSSIDE SODIUM; PIMOBENDAN; PLACEBO; TROPONIN C;

ACUTE DECOMPENSATED HEART FAILURE; ACUTE HEART FAILURE; CALCIUM CELL LEVEL; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; DIASTOLE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART SURGERY; HEART VENTRICLE EXTRASYSTOLE; HEMODYNAMIC MONITORING; HUMAN; HYPOKALEMIA; HYPOTENSION; INOTROPISM; LUNG BLOOD VESSEL; LUNG CAPILLARY PRESSURE; MAXIMUM PERMISSIBLE DOSE; MORBIDITY; MORTALITY; NONHUMAN; OUTPATIENT CARE; REVIEW; SHOCK; SURVIVAL; TACHYCARDIA; VASODILATATION;

ACUTE DISEASE; CALCIUM; CARDIAC OUTPUT; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; PULMONARY WEDGE PRESSURE; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 30644462466     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Senni M, De Maria R, Gregori D, Gonzini L, Gorini M, Cacciatore G et al. Temporal trends in survival and hospitalizations in outpatients with chronic systolic heart failure in 1995 and 1999. J Card Fail 2005;11:270-8.
2. O'Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HP registry. J Card Fail 2005;11:200-5.
3. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002;4:361-71.
4. McGowan B, Heerey A, Ryan M, Barry M. Cost of treating heart failure in an Irish teaching hospital. Ir J Med Sci 2000;169:241-4.
5. Polanczyk CA, Rohde LE, Dec GW, DiSalvo T. Ten-year trends in hospital care for congestive heart failure: improved outcomes and increased use of resources. Arch Intern Med 2000;160:325-32.
6. Ryden-Bergsten T, Andersson F. The health care costs of heart failure in Sweden. J Intern Med 1999;246:275-84.
7. Nieminen MS, Bohm M, Cowie MR, Filippatos GS, Jondeau G, Hasin Y et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
8. Stevenson LW. Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail 1999;1:251-7.
9. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002;105:1348-53.
10. Oren RM. Hyponatremia in congestive heart failure. Am J Cardiol 2005;95(9A):2B-7B.
11. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-7.
12. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 2001;142:393-401.
13. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-75.
14. Fonarow GC, Corday E. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev 2004;9:179-85.
15. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998;98:2141-7.
16. Haikala H, Kaheinen P, Levijoki J, Linden IB. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 1997;34:536-46.
17. Boknik P, Neumann J, Kaspareit G, Schmitz W, Scholz H, Vahlensieck U et al. Mechanisms of the contractile effects of levosimendan in the mammalian heart. J Pharmacol Exp Ther 1997;280:277-83.
18. Kato K. Clinical efficacy and safety of pimobendan in treatment of heart failure-experience in Japan. Cardiology 1997;88 Suppl 2:28-36.
19. Katz SD, Kubo SH, Jessup M, Brozena S, Troha JM, Wahl J et al. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Am Heart J 1992;123:95-103.
20. Lubsen J, Just H, Hjalmarsson AC, La Framboise D, Remme WJ, Heinrich-Nols J et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996;76:223-31.
21. Remme WJ, Krayenbuhl HP, Baumann G, Frick MH, Haehl M, Nehmiz G et al. Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group. Eur Heart J 1994;15:947-56.
22. Sasayama S, Asanoi H, Kihara Y, Yokawa S, Terada Y, Yoshida S et al. Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. Heart Vessels 1994;9:113-20.
23. Effects of Pimobendan on Chronic Heart Failure Study (EPOCH Study). Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). Circ J 2002;66:149-57.
24. Haikala H, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol 1995;27:2155-65.
25. Edes I, Kiss E, Kitada Y, Powers FM, Papp JG, Kranias EG et al. Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995;77:107-13.
26. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac froponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-66.
27. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 1994;269:28584-90.
28. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995;25:794-801.
29. Pagel PS, Harkin CP, Hettrick DA, Warltier DC. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology 1994;81:974-87.
30. Tachibana H, Cheng HJ, Ukai T, Igawa A, Zhang ZS, Little WC et al. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol Heart Circ Physiol 2005;288:H914-22.
31. Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005;96:423-6.
32. Hampton JR, van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997;349:971-7.
33. Todaka K, Wang J, Yi GH, Stennett R, Knecht M, Packer M et al. Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther 1996;279:120-7.
34. Hasenfuss G, Pieske B, Kretschmann B, Holubarsch C, Alpert NR, Just H. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J Cardiovasc Pharmacol 1995;26 Suppl 1:S45-51.
35. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000;68:522-31.
36. Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Lehikoinen P, Nagren K et al. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 1997;61:596-607.
37. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999;34:219-28.
38. Jamali IN, Kersten JR, Pagel PS, Hettrick DA, Warltier DC. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 1997;85:23-9.
39. Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Ferrer-Hita JJ. Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: a series of cases. J Clin Pharmacol 2005;45:704-8.
40. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peunkurinen K et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
41. Harkin CP, Pagel PS, Tessmer JP, Warltier DC. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J Cardiovasc Pharmacol 1995;26:179-88.
42. Pataricza J, Hohn J, Petri A, Balogh A, Papp J. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 2000;52:213-7.
43. Pataricza J, Krassoi I, Hohn J, Kun A, Papp J. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 2003;17:115-21.
44. De Witt BJ, Ibrahim IN, Bayer E, Fields AM, Richards TA, Banister RE et al. An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg 2002;94:1427-33, table of contents.
45. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide- sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 1997;333:249-59.
46. Kaheinen P, Pollesello P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 2001;37:367-74.
47. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, Bang L, Olesen SP, Aldershvile J. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998;31:741-9.
48. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 1999;288:316-25.
49. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther 1997;283:375-83.
50. Kopustinskiene DM, Pollesello P, Saris NE. Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol 2001;428:311-4.
51. Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol 2004;68:807-12.
52. Rump AF, Acar D, Klaus W. A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated heans. Br J Pharmacol 1994;112:757-62.
53. Rump AF, Acar D, Rosen R, Klaus W. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol Toxicol 1994;74:244-8.
54. Lilleberg J, Antila S, Karlsson M, Nieminen MS, Pentkainen PJ. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers. Clin Pharmacol Ther 1994;56:554-63.
55. Sandell EP, Hayha M, Antila S, Heikkinen P, Ottoila P, Lehtonen IA et al. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol 1995;26 Suppl 1:857-62.
56. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002;40:465-71.
57. (Abbott Scandinavia AB). Levosimendan Concentrate for Solution for Infusion. 2004 November 9.
58. Takahashi R, Talukder MA, Endoh M. Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium. J Cardiovasc Pharmacol 2000;36:118-25.
59. Takahashi R, Talukder MA, Endoh M. Inotropic effects of OR-1896, an active metabolite of levosimendan. on canine ventricular myocardium. Eur J Pharmacol 2000;400:103-12.
60. Takahashi R, Endoh M. Effects of OR-1896, a metabolite of levosimendan, on force of contraction and Ca2+ transients under acidotic condition in aequorin-loaded canine ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 2002;366:440-8.
61. Antila S, Pesonen U, Lehtonen L, Tapanainen P, Nikkanen H, Vaahtera K et al. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur J Pharm Sci 2004;23:213-22.
62. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 2002;42:43-51.
63. Sandell E, Aalto T, Antila S et al. The effects of severe congestive heart failure on the pharmacokinetics of levosimendan. Eur J Clin Pharmacol 1997;52 Suppl:55.
64. Sandell E, Antilla S, Koistinen H, Pentikainen P. The effects of renal failure on the pharmacokinetics of levosimendan. 1st Congress of the European Association for Clinical Pharmacology and Therapeutics, 1995, 27-30 September, Paris, France.
65. Antila S, Jarvinen A, Honkanen T, Lehtonen L. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin. Eur J Clin Pharmacol 2000;56:705-10.
66. Lehtonen L, Antilla S, Eha J. No pharmacodynamic interactions between a new calcium sensitizing drug levosimendan and a calcium antagonist drug felodipine. Eur J Clin Pharmacol 1997;52 Suppl:136.
67. Antila S, Honkanen T, Lehtonen L, Neuvonen PJ. The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan. Int J Clin Pharmacol Ther 1998;36:446-9.
68. Antila S, Eha J, Heinpalu M, Lehtonen L, Loogna I, Mesikepp A et al. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol 1996;49:451-8.
69. Sundberg S, Lehtonen L. Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects. Eur J Clin Pharmacol 2000;55:793-9.
70. Lehtonen L, Sundberg S. The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects. Eur J Clin Pharmacol 2002;58:449-52.
71. Antila S, Jarvinen A, Akkila J, Honkanen T, Karlsson M, Lehtonen L. Studies on psychomotoric effects and pharmacokinetic interactions of the new calcium sensitizing drug levosimendan and ethanol. Arzneimittelforschung 1997;47:816-20.
72. Lilleberg J, Sundberg S, Nieminen MS. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1995;26 Suppl 1:563-9.
73. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903-12.
74. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000;102:2222-7.
75. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSIAN). Eur Heart J 2002;23:1422-32.
76. Zairis MN. Apostolatos C, Anastassiadia F. Comparison of the effect of levosimendan, or dobutamine or placebo in chronic low output decompensated heart failure. Calcium Sensitizer or Inotrope or None in low output heart failure (CASINO) study. European Society of Cardiology, Heart Failure Update. Wroclaw, Poland; 2004.
77. Garratt C, Packer M, Colucci WS, Fisher L, Massie B, Teerlink J et al. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE-1 study. J Card Fail 2003;9:S61.
78. Mebazaa A, Cohen-Solal A, Kleber FX. Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure. Annual Scientific Meeting of the Heart Failure Society of America. Toronto, Canada; 2004.
79. Cleland JG, Takala A, Apajasalo M, Zethraeus N, Kobelt G. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. Eur J Heart Fail 2003;5:101-8.
80. Lilleberg J, Nieminen MS, Akkila J, Heikkila L, Kuitunen A, Lehtonen L et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998;19:660-8.
81. Sundberg S, Lilleberg J, Nieminen MS, Lehtonen L. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am J Cardiol 1995;75:1061-6.
82. Toivonen L, Viitasalo M, Sundberg S, Akkila J, Lehtonen L. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J Cardiovasc Pharmacol 2000;35:664-9.
83. Nanas JN, Papazoglou PP, Terrovitis JV, Kanakakis J, Dalianis A, Tsolakis E et al. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol 2004;94:1329-32.
84. Adams KF Jr, Fonarow GC, Emerman CL, Lejemtel TH, Costanzo MR, Abraham WT et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-16.
85. Kyrzopoulos S, Adamopoulos S, Parissis JT, Rassias J, Kostakis G, Iliodromitis E et al. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol 2005;99:409-13.
86. Mueller T, Gegenhuber A, Haltmayer M. Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure. Int J Cardiol 2005;104:355-6; author reply 357-8. Epub 2005 Jun 9.
87. Adamopoulos S, Parissis JT, Farmakis D, Kremastinos DT. Levosimendan therapy in decompensated chronic heart failure: effects on natriuretic peptides and hemodynanic parameters. Int J Cardiol 2005;104:357-8. Epub 2005 Jun 8.
88. Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, Demopoulou M, Missovoulos P, Androulakis A et al. The Ca(2+)-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 2005;7:882-7
89. Nanas JN, Papazoglou P, Tsagalou EP, Ntalianis A, Tsolakis E, Terrovitis JV et al. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am J Cardiol 2005;95:768-71.
90. Grundeman PF, Borst C, van Herwaarden JA, Mansvelt Beck HJ, Jansen EW. Hemodynamic changes during displacement of the beating heart by the Utrecht Octopus method. Ann Thorac Surg 1997;63(6 Suppl):S88-92.
91. Barisin S, Husedzinovic I, Sonicki Z, Bradic N, Barisin A, Tonkovic D. Levosimendan in off-pump coronary artery bypass: a four-times masked controlled study. J Cardiovasc Pharmacol 2004;44:703-8.
92. Labriola C, Siro-Brigiani M, Carrata F, Santangelo E, Amantea B. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther 2004;42:204-11.
93. Lochner A, Colesky F, Genade S. Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic inotropic response of the myocardium. Cardiovasc Drugs Ther 2000;14:271-81.
94. Eriksson O, Pollesello P, Haikala H. Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion. J Cardiovasc Pharmacol 2004;44:316-21.
95. Toller W, Wolkart G, Stranz C, Metzler H, Brunner F. Contractile action of levosimendan and epinephrine during acidosis. Eur J Pharmacol 2005;507:199-209.
96. Takahashi R, Endoh M. Dual regulation of myofilament Ca(2+) sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium. Br J Pharmacol 2005;145:1143-52.
97. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993;328:1471-7.
98. Silverman HJ, Penaranda R, Orens JB, Lee NH. Impaired beta-adrenergic receptor stimulation of cyclic adenosine monophosphate in human septic shock: association with myocardial hyporesponsiveness to catecholamines. Crit Care Med 1993;21:31-9.
99. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996;183:949-58.
100. Plochl W, Rajek A. The use of the novel calcium sensitizer levosimendan in critically ill patients. Anaesth Intensive Care 2004;32:471-5.
101. Schwarte LA, Picker O, Bornstein SR, Fournell A, Scheeren TW. Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs. Crit Care Med 2005;33:135-42; discussion 246-7.
102. Morelli A, De Castro S, Teboul JL, Singer M, Rocco M, Conti G, De Luca L et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005;31:638-44.
103. Lehmann A, Lang J, Boldt J, Isgro F, Kiessling AH. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit 2004;10:MT89-93.